×
Chugai Pharmaceutical Receivables 2020-2023 | CHGCY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Chugai Pharmaceutical receivables from 2020 to 2023. Receivables can be defined as the total amount of collectibles for a company
View More
Chugai Pharmaceutical Receivables 2020-2023 | CHGCY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Chugai Pharmaceutical receivables from 2020 to 2023. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$88.3B
Takeda Pharmaceutical (TAK)
$46.6B
Merck (MKGAF)
$23B
Astellas Pharma (ALPMY)
$21.6B
Sandoz Group AG (SDZNY)
$18.1B
Summit Therapeutics (SMMT)
$16.5B
United Therapeutics (UTHR)
$15.9B
Shionogi (SGIOY)
$13.3B
Neurocrine Biosciences (NBIX)
$11.7B
Catalent (CTLT)
$10.9B
Orion OYJ (ORINY)
$7.7B
Revolution Medicines (RVMD)
$7.3B
Jazz Pharmaceuticals (JAZZ)
$6.8B
Ionis Pharmaceuticals (IONS)
$6B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$4.6B
Corcept Therapeutics (CORT)
$4.5B
Crinetics Pharmaceuticals (CRNX)
$4B
Dyne Therapeutics (DYN)
$3.5B
PTC Therapeutics (PTCT)
$2.9B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.6B
Arrowhead Pharmaceuticals (ARWR)
$2.4B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Recursion Pharmaceuticals (RXRX)
$2B
Soleno Therapeutics (SLNO)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Xencor (XNCR)
$1.6B
Harrow (HROW)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Cassava Sciences (SAVA)
$1.5B